Publikace
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart2018 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Neonatal capsaicin administration impairs postnatal development of the cardiac chronotropy and inotropy in rats2016 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Plzni, 1. lékařská fakulta
- Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium2013 | Farmaceutická fakulta v Hradci Králové
- Role of glutathione in anthracycline-induced cardiotoxicityPublikace bez příslušnosti k fakultě
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity2020 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline2019 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
Loading network view...
